Roles of T lymphocytes in pulmonary fibrosis
The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Infiltration of T lymphocytes in the lungs is common in patients with and in animal models of pulmonary fibrosis. The role of these cells in regulating the accumulation of extracellular matrix, particularly collagen, is not understood completely. Research literature provides evidence for a profibrotic, an antifibrotic, or no significant role of T lymphocytes in pulmonary fibrosis. This review offers a discussion of such evidence with the focus on phenotypes of pulmonary T lymphocytes and related profibrotic and antifibrotic mechanisms. It appears unlikely that T lymphocytic infiltration per se is the central driving force in most cases of pulmonary fibrosis. Instead, evidence suggests that T lymphocytes may modulate the inflammatory and healing responses in the lungs in a profibrotic or antifibrotic manner, depending on their phenotype. Phenotypic reshaping, rather than elimination of the infiltrating pulmonary T lymphocytes, may be a promising approach to improving outcomes in patients with pulmonary fibrosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Here, Th1 cells and their secretory products are thought of as being anti-fibrotic and Th2 cells and their mediators are considered pro-fibrotic (133).”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [133]
Citations
Cites
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z., & Oster, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-163oc · Cited by 1,310 · cited 2×
“new patients per year in the United States [2].”
BackgroundIdiopathic Pulmonary Fibrosis: Clinical Relevance of Pathologic Classification
KATZENSTEIN, A.-L. A., & MYERS, J. L. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707039 · Cited by 1,261
IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines
Molet, S., Hamid, Q., Davoineb, F., Nutku, E., Tahaa, R., Pagé, N., Olivenstein, R., Elias, J., & Chakir, J. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.117929 · Cited by 953 · cited 1×
“IL-17 enhances production of cytokines in cultured, pulmonary fibroblasts but appears to have no direct effect on fibroblast proliferation or collagen production [52].”
BackgroundA placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
Raghu, G., Brown, K. K., Bradford, W. Z., Starko, K., Noble, P. W., Schwartz, D. A., & King, T. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030511 · Cited by 652
Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis.
Piguet, P. F., Collart, M. A., Grau, G. E., Kapanci, Y., & Vassalli, P. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.3.655 · Cited by 583 · cited 1×
“In contrast, different studies in the bleomycin model reported that depletion of T cells prevents collagen accumulation [34] or diminishes pulmonary fibrosis and increases survival [35].”
ResultA Vicious Circle of Alveolar Macrophages and Fibroblasts Perpetuates Pulmonary Fibrosis via CCL18
Prasse, A., Pechkovsky, D. V., Toews, G. B., Jungraithmayr, W., Kollert, F., Goldmann, T., Vollmer, E., Müller-Quernheim, J., & Zissel, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200509-1518oc · Cited by 497 · cited 1×
“For example, activation of alveolar macrophages with type 2 cytokines skews their phenotype toward so-called alternative activation, and alternatively activated macrophages are themselves profibrotic [49] through production of various cytokines including profibrotic chemokines CCL2 [42] and CCL18 [50, 51].”
BackgroundBleomycin-induced interstitial pulmonary disease in the nude, athymic mouse.
Szapiel, S. V., Elson, N., Fulmer, J. D., Hunninghake, G. W., & Crystal, R. G. (1979) · PubMed · doi:10.1164/arrd.1979.120.4.893 · Cited by 463 · cited 1×
“Mice with genetic defects manifesting in a total lack of T lymphocytes, such as athymic (nude) mice [27] and SCID mice [28], developed alveolitis and pulmonary fibrosis in response to bleomycin, similar to that in normal (wild-type) mice.”
BackgroundDANIIL, Z. D., GILCHRIST, F. C., NICHOLSON, A. G., HANSELL, D. M., HARRIS, J., COLBY, T. V., & du BOIS, R. M. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.3.9903021 · Cited by 381
Mart�nez-Lav�n, M., Hermosillo, A. G., Rosas, M., & Soto, M.-E. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199811)41:11<1966::aid-art11>3.0.co;2-o · Cited by 306
Structural Features of Interstitial Lung Disease in Systemic Sclerosis
Harrison, N. K., Myers, A. R., Corrin, B., Soosay, G., Dewar, A., Black, C. M., Du Bois, R. M., & Turner-Warwick, M. (1991) · American Review of Respiratory Disease · doi:10.1164/ajrccm/144.3_pt_1.706 · Cited by 251 · cited 2×
“Pulmonary fibrosis often occurs in association with systemic connective tissue diseases, particularly scleroderma [4, 12], rheumatoid arthritis (RA) [14], and polymyositis/dermatomyositis [15, 16].”
Background
Research works printed but not linked: 1
- Huaux, 2007, ThIL-17 cells contribute to alveolitis but are not instrumental in fibrosis development, Am. J. Respir. Crit. Care Med., 175, A737
Cited by
Shared and distinct mechanisms of fibrosis
Distler, J. H. W., Györfi, A.-H., Ramanujam, M., Whitfield, M. L., Königshoff, M., & Lafyatis, R. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0322-7 · Cited by 637
Regulation of inflammation by interleukin-4: a review of "alternatives"
Luzina, I. G., Keegan, A. D., Heller, N. M., Rook, G. A. W., Shea-Donohue, T., & Atamas, S. P. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0412214 · Cited by 351
Self-citationImmune mechanisms in pulmonary fibrosis
Kolahian, S., Fernandez, I. E., Eickelberg, O., & Hartl, D. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0121tr · Cited by 349
T Cells in Fibrosis and Fibrotic Diseases
Zhang, M., & Zhang, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01142 · Cited by 330
“However, the functions of each T cell subset appear to be perplexing and are influenced by interactions with epithelial cells or fibroblasts, the pulmonary localization of fibrosis in the bronchial or alveolar region, and the disease progression stage (9, 10).”
BackgroundThe Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis
Desai, O., Winkler, J., Minasyan, M., & Herzog, E. L. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00043 · Cited by 314
“Here, Th1 cells and their secretory products are thought of as being anti-fibrotic and Th2 cells and their mediators are considered pro-fibrotic (133).”
Backgroundγδ T cells protect against lung fibrosis via IL-22
Simonian, P. L., Wehrmann, F., Roark, C. L., Born, W. K., O'Brien, R. L., & Fontenot, A. P. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100061 · Cited by 242
“, rheumatoid arthritis and systemic sclerosis), idiopathic PF, and sarcoidosis, its pathogenesis is poorly understood with few therapeutic options that arrest progression of fibrotic disease (Luzina et al., 2008).”
BackgroundGlobal impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis
Kotsianidis, I., Nakou, E., Bouchliou, I., Tzouvelekis, A., Spanoudakis, E., Steiropoulos, P., Sotiriou, I., Aidinis, V., Margaritis, D., Tsatalas, C., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200812-1936oc · Cited by 230
Murray, L. A., Rosada, R., Moreira, A. P., Joshi, A., Kramer, M. S., Hesson, D. P., Argentieri, R. L., Mathai, S., Gulati, M., Herzog, E. L., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009683 · Cited by 192
“Moreover, the role of T cells during lung fibrosis is controversial [16] and further studies with potential advances in technology to help delineate the cellular source of IL13 would add to our current understanding.”
BackgroundCellular and Molecular Mechanisms of Chronic Inflammation-Associated Organ Fibrosis
Ueha, S., Shand, F. H. W., & Matsushima, K. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00071 · Cited by 182
“While a number of studies suggest an exacerbating role of T cells in fibrosis, T cells also appear to be dispensable because T cell-deficient mice develop fibrosis in some models (Luzina et al., 2008).”
BackgroundJun, D., Garat, C., West, J., Thorn, N., Chow, K., Cleaver, T., Sullivan, T., Torchia, E. C., Childs, C., Shade, T., et al. (2011) · Stem Cells · doi:10.1002/stem.604 · Cited by 155
Mechanisms of Oncostatin M-Induced Pulmonary Inflammation and Fibrosis
Mozaffarian, A., Brewer, A. W., Trueblood, E. S., Luzina, I. G., Todd, N. W., Atamas, S. P., & Arnett, H. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.7243 · Cited by 153
“Although both T cells and mast cells have been shown to express OSM in abundance in a variety of inflammatory situations, a recent review suggests that these cells are not always the drivers of pulmonary fibrosis and may only modulate the response (42).”
BackgroundSelf-citationLo Re, S., Dumoutier, L., Couillin, I., Van Vyve, C., Yakoub, Y., Uwambayinema, F., Marien, B., van den Brûle, S., Van Snick, J., Uyttenhove, C., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0900459 · Cited by 142
“numerous fibroproliferative lung disorders (61).”
BackgroundAcute toxicity of nickel nanoparticles in rats after intravenous injection
Zhao, J., Magaya, R. R., Zou, B., Shi, H., Yu, H., Yue, X., Liu, K., Lin, X., Xu, J., Yang, C., et al. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s56212 · Cited by 137
“The infiltrates were mostly composed of lymphocytes; T lymphocytes are thought to be both pro and anti-fibrotic.(20) Other studies involving Ni oxide nanoparticles have also reported the presence of lymphocytic infiltrates in the lung.”
BackgroundImmune Mechanisms of Pulmonary Fibrosis with Bleomycin
Ishida, Y., Kuninaka, Y., Mukaida, N., & Kondo, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043149 · Cited by 137
Reilkoff, R. A., Peng, H., Murray, L. A., Peng, X., Russell, T., Montgomery, R., Feghali-Bostwick, C., Shaw, A., Homer, R. J., Gulati, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201206-1109oc · Cited by 135
“The role of lymphocytes in experimentally induced and human lung fibrosis is controversial (10).”
BackgroundInterleukin-33 Potentiates Bleomycin-Induced Lung Injury
Luzina, I. G., Kopach, P., Lockatell, V., Kang, P. H., Nagarsekar, A., Burke, A. P., Hasday, J. D., Todd, N. W., & Atamas, S. P. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0093oc · Cited by 120
“IL-33–expressing cells were abundant in the inflammatory infiltrates (see Figure E1 in the online supplement), which are known to consist mostly of lymphocytes, whereas only occasional macrophages, neutrophils, and eosinophils are present in the pulmonary infiltrates of these patients (7, 29, 31, 33, 35, 45).”
BackgroundSelf-citationPlatelet-derived growth factor-producing CD4+ Foxp3+ regulatory T lymphocytes promote lung fibrosis
Lo Re, S., Lecocq, M., Uwambayinema, F., Yakoub, Y., Delos, M., Demoulin, J.-B., Lucas, S., Sparwasser, T., Renauld, J.-C., Lison, D., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201103-0516oc · Cited by 128
“Evidence is accumulating that T eff cells also participate in the pathogenesis of fibrosis (6, 7).”
MicroRNAs as potential targets for progressive pulmonary fibrosis
Rajasekaran, S., Rajaguru, P., & Paramasivam, S. G. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00254 · Cited by 127
Mohning, M. P., Downey, G. P., Cosgrove, G. P., & Redente, E. F. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54431-3.00003-2 · Cited by 123
Todd, N., Scheraga, Galvin, Iacono, Britt, Luzina, Burke, & Atamas (2013) · Journal of Inflammation Research · doi:10.2147/jir.s40673 · Cited by 113
Self-citationDifferential role of regulatory T cells in early and late stages of pulmonary fibrosis
Boveda-Ruiz, D., D’Alessandro-Gabazza, C. N., Toda, M., Takagi, T., Naito, M., Matsushima, Y., Matsumoto, T., Kobayashi, T., Gil-Bernabe, P., Chelakkot-Govindalayathil, A.-L., et al. (2013) · Immunobiology · doi:10.1016/j.imbio.2012.05.020 · Cited by 110
Bronchoalveolar lavage cell pattern from healthy human lung
Heron, M., Grutters, J. C., ten Dam-Molenkamp, K. M., Hijdra, D., van Heugten-Roeling, A., Claessen, A. M. E., Ruven, H. J. T., van den Bosch, J. M. M., & van Velzen‐Blad, H. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04529.x · Cited by 110
Simonian, P. L., Roark, C. L., Wehrmann, F., Lanham, A. M., Born, W. K., O'Brien, R. L., & Fontenot, A. P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900013 · Cited by 95
“Although T cells are important in the pathogenesis of HP, their role in the development of pulmonary fibrosis remains poorly understood (25).”
BackgroundProfibrotic Activities for Matrix Metalloproteinase-8 during Bleomycin-Mediated Lung Injury
Craig, V. J., Quintero, P. A., Fyfe, S. E., Patel, A. S., Knolle, M. D., Kobzik, L., & Owen, C. A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201043 · Cited by 91
Chiang, G. C., & Parimon, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032405 · Cited by 103
“Additionally, bronchoalveolar lavages from patients with SSc-ILD, RA-ILD, and inflammatory myositis have an accumulation of T cells with a predominance of cytotoxic CD8+ T cells [62].”
BackgroundThe cytokines of pulmonary fibrosis: Much learned, much more to learn
Luzina, I. G., Todd, N. W., Sundararajan, S., & Atamas, S. P. (2014) · Cytokine · doi:10.1016/j.cyto.2014.11.008 · Cited by 100
Self-citationA Role for Dendritic Cells in Bleomycin-induced Pulmonary Fibrosis in Mice?
Bantsimba-Malanda, C., Marchal-Sommé, J., Goven, D., Freynet, O., Michel, L., Crestani, B., & Soler, P. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200907-1164oc · Cited by 86
Luzina, I. G., Todd, N. W., Nacu, N., Lockatell, V., Choi, J., Hummers, L. K., & Atamas, S. P. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24435 · Cited by 86
“This model is more suitable for the current study than is a more traditional model of bleomycin-induced pulmonary fibrosis, because the bleomycin model is known to be T cell independent (2,20,21).”
InfluentialSelf-citationCytokines in chronic respiratory diseases
Atamas, S. P., Chapoval, S. P., & Keegan, A. D. (2013) · F1000 Biology Reports · doi:10.3410/b5-3 · Cited by 92
“All these mechanisms are controlled by cytokines, either through direct recruitment and activation of extracellular matrix-producing cells, or indirectly, through regulation of pulmonary inflammation [124-130], redox balance [131-133], and activity of several enzymatic systems, including matrix metalloproteinases and…”
BackgroundSelf-citationIL‐17A deficiency mitigates bleomycin‐induced complement activation during lung fibrosis
Cipolla, E., Fisher, A. J., Gu, H., Mickler, E. A., Agarwal, M., Wilke, C. A., Kim, K. K., Moore, B. B., & Vittal, R. (2017) · The FASEB Journal · doi:10.1096/fj.201700289r · Cited by 89
T cells in idiopathic pulmonary fibrosis: crucial but controversial
Deng, L., Huang, T., & Zhang, L. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01344-x · Cited by 74
“However, due to the effect of TGF-β production, which results in fibroblast proliferation, Tregs are recognized as promoting fibrosis progression [75, 76].”
BackgroundImplications of the Immune Landscape in COPD and Lung Cancer: Smoking Versus Other Causes
Taucher, E., Mykoliuk, I., Lindenmann, J., & Smolle-Jüettner, F.-M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.846605 · Cited by 86
Gan, Y., Reilkoff, R., Peng, X., Russell, T., Chen, Q., Mathai, S. K., Homer, R., Gulati, M., Siner, J., Elias, J., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30386 · Cited by 83
Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis
Tzouvelekis, A., Toonkel, R. L., Karampitsakos, Τ., Medapalli, K., Ninou, I., Aidinis, V., Bouros, D. E., & Glassberg, M. K. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00142 · Cited by 82
IL-21 Promotes Pulmonary Fibrosis through the Induction of Profibrotic CD8+ T Cells
Brodeur, T. Y., Robidoux, T. E., Weinstein, J. S., Craft, J. E., Swain, S. L., & Marshak‐Rothstein, A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500777 · Cited by 79
New insights into the molecular pathology of radiation-induced pneumopathy
Cappuccini, F., Eldh, T., Bruder, D., Gereke, M., Jastrow, H., Schulze‐Osthoff, K., Fischer, U., Köhler, D., Stuschke, M., & Jendrossek, V. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.05.064 · Cited by 78
“The obvious dual role of lymphocytes for radiation-induced pneumopathy is reminiscent of results obtained in the model of bleomycin-induced pneumopathy [26, 27] and requires further definition.”
Popat, R. J., Hakki, S., Thakker, A., Coughlan, A. M., Watson, J., Little, M. A., Spickett, C. M., Lavender, P., Afzali, B., Kemper, C., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.87379 · Cited by 77
“T cells have been shown to be important in both pulmonary (55) and renal fibrosis (56), with several potential mechanisms that have not been fully defined.”
Idiopathic pulmonary fibrosis (IPF) signaling pathways and protective roles of melatonin
Hosseinzadeh, A., Javad-Moosavi, S. A., Reiter, R. J., Hemati, K., Ghaznavi, H., & Mehrzadi, S. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.03.032 · Cited by 77
γδ T Cells Attenuate Bleomycin-Induced Fibrosis through the Production of CXCL10
Pociask, D. A., Chen, K., Choi, S. M., Oury, T. D., Steele, C. H., & Kolls, J. K. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.11.055 · Cited by 76
“The role of T cells in fibrosis is a topic of debate.(34) In line with the current studies, there is growing literature that certain subsets of T cells are beneficial because mice with severe combined immunodeficiency developed more severe fibrosis in response to asbestos, which was reduced on reconstitution with T ce…”
ResultEvidence for a Functional Thymic Stromal Lymphopoietin Signaling Axis in Fibrotic Lung Disease
Datta, A., Alexander, R., Sulikowski, M. G., Nicholson, A. G., Maher, T. M., Scotton, C. J., & Chambers, R. C. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300588 · Cited by 73
GM-CSF but Not IL-17 Is Critical for the Development of Severe Interstitial Lung Disease in SKG Mice
Shiomi, A., Usui, T., Ishikawa, Y., Shimizu, M., Murakami, K., & Mimori, T. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303255 · Cited by 62
“CD8 T cells (30, 31), as well as some subtypes of CD4 T cells, including Th2, regulatory T cells, and Th17 cells (32, 33), and neutrophils (5–8) are reported as contributors of pulmonary fibrosis.”
BackgroundSivakumar, P., Thompson, J. R., Ammar, R., Porteous, M. K., McCoubrey, C., Cantu, E., Ravi, K., Zhang, Y., Luo, Y., Streltsov, D., et al. (2019) · ERJ Open Research · doi:10.1183/23120541.00117-2019 · Cited by 74
Increased incidence of autoimmune markers in patients with combined pulmonary fibrosis and emphysema
Τzouvelekis, Α., Zacharis, G., Oikonomou, A., Mikroulis, D. A., Margaritopoulos, G. A., Koutsopoulos, A. V., Ántoniadis, A., Koulelidis, A., Steiropoulos, P., Boglou, P., et al. (2013) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-13-31 · Cited by 71
“In the past, despite seminal reports pointing to an association between immune deregulation and paradigms of chronic lung injury [6], the role of autoimmunity in the pathogenetic cascade of both idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) has been severely overlooked mainly due…”
BackgroundLuzina, I. G., Salcedo, M. V., Rojas-Peña, M. L., Wyman, A. E., Galvin, J. R., Sachdeva, A., Clerman, A., Kim, J., Franks, T. J., Britt, E. J., et al. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.01.002 · Cited by 65
“Elevations in the expression of numerous immunity- and inflammation-related genes (Figure 5B) have been associated with pulmonary fibrosis in the past [22, 24], including T and B lymphocyte-specific molecules such as the CD3 chains, MS4A1/CD20, CD79A, CD40LG, and FASLG [52-54].”
BackgroundSelf-citationIron-Dependent Mitochondrial Dysfunction Contributes to the Pathogenesis of Pulmonary Fibrosis
Takahashi, M., Mizumura, K., Gon, Y., Shimizu, T., Kozu, Y., Shikano, S., Iida, Y., Hikichi, M., Okamoto, S., Tsuya, K., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.643980 · Cited by 68
“However, it appears unlikely that T lymphocytic infiltration per se is the central driving force for fibrotic processes in most cases of pulmonary fibrosis (Helene et al., 1999; Luzina et al., 2008).”
BackgroundCD147 contributes to SARS-CoV-2-induced pulmonary fibrosis
Wu, J., Chen, L., Qin, C., Huo, F., Liang, X., Yang, X., Zhang, K., Lin, P., Liu, J., Feng, Z., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01230-5 · Cited by 67
“Th2 secreted cytokines such as IL-4, IL-5 and IL-13 that promote pulmonary fibrosis, whereas Th1 cytokines IFN-γ and IL-12 inhibit fibrogenesis.(19,20) Previous studies also support a role for Th17 cells and its cytokine IL-17 in different murine pulmonary fibrosis models, since neutralization of IL-17A promoted the r…”
BackgroundCD4+ T lymphocytes in lung fibrosis: diverse subsets, diverse functions
Re, S. L., Lison, D., & Huaux, F. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0512261 · Cited by 68
“For example, CD4 and especially CD8 T cells are capable of producing CCL3 (MIP-1 ), and this chemokine is involved in pulmonary recruitment of fibrocytes in association with development of pulmonary fibrosis in an animal model [25].”
BackgroundInfluentialPulmonary CCR2+CD4+T cells are immune regulatory and attenuate lung fibrosis development
Milger, K., Yu, Y., Brudy, E., Irmler, M., Skapenko, A., Mayinger, M. C., Lehmann, M., Beckers, J., Reichenberger, F., Behr, J., et al. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-208423 · Cited by 66
γδ T cells and Th17 cytokines in hypersensitivity pneumonitis and lung fibrosis
Simonian, P. L., Roark, C. L., Born, W. K., O’Brien, R. L., & Fontenot, A. P. (2009) · Translational research · doi:10.1016/j.trsl.2009.08.006 · Cited by 65
Resolution of bleomycin-induced murine pulmonary fibrosis via a splenic lymphocyte subpopulation
Kamio, K., Azuma, A., Matsuda, K., Usuki, J., Inomata, M., Morinaga, A., Kashiwada, T., Nishijima, N., Itakura, S., Kokuho, N., et al. (2018) · Respiratory Research · doi:10.1186/s12931-018-0783-2 · Cited by 62
“Immunosuppressive Tregs represent a novel T cell sub-population that is expected to act profibrotically [10].”
BackgroundResultPulmonary toxicants and fibrosis: innate and adaptive immune mechanisms
Malaviya, R., Kipen, H. M., Businaro, R., Laskin, J. D., & Laskin, D. L. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115272 · Cited by 59
Regulatory T cells are a double-edged sword in pulmonary fibrosis
Wang, F., Xia, H., & Yao, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106443 · Cited by 60
Roybal, C. N., Velez, G., Toral, M. A., Tsang, S. H., Bassuk, A. G., & Mahajan, V. B. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.11.025 · Cited by 56
“Tcells are key regulators in fibrosis.(42,43) A Th1-response is most likely anti-fibrotic and Th2-response is most likely pro-fibrotic.”
STAT3: A Central Mediator of Pulmonary Fibrosis?
Prêle, C. M., Yao, E., O’Donoghue, R. J. J., Mutsaers, S. E., & Knight, D. A. (2012) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201201-007aw · Cited by 53
Xu, L., Xiong, S., Guo, R., Yang, Z., Wang, Q., Xiao, F., Wang, H., Pan, X., & Zhu, M. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.06.010 · Cited by 53
Kass, D. J., Yu, G., Loh, K. S., Savir, A., Borczuk, A., Kahloon, R., Juan-Guardela, B., Deiuliis, G., Tedrow, J., Choi, J., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.01.010 · Cited by 51
Nikota, J. K., Banville, A. C., Goodwin, L. R., Wu, D., Williams, A., Yauk, C. L., Wallin, H., Vogel, U. B., & Halappanavar, S. S. (2017) · Particle and Fibre Toxicology · doi:10.1186/s12989-017-0218-0 · Cited by 53
“the interaction between inflammation and fibrosis could be 1) direct – the underlying mechanisms that drive MWCNT-induced inflammation also drive the fibrosis pathology, 2) indirect – the mechanisms driving MWCNT-induced inflammation and lung fibrosis are initiated independently but some level of interaction between t…”
BackgroundPeng, X., Moore, M. W., Peng, H., Sun, H., Gan, Y., Homer, R. J., & Herzog, E. L. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00080 · Cited by 49
Xie, Y., Shi, S., Lv, W., Wang, X., Yue, L., Deng, C., Wang, D., Han, J., Ye, T., & Lin, Y. (2024) · ACS Nano · doi:10.1021/acsnano.4c06598 · Cited by 54
Liu, M., Zeng, X., Wang, J., Fu, Z., Wang, J., Liu, M., Ren, D., Yu, B., Zheng, L., Hu, X., et al. (2016) · Stem Cell Research & Therapy · doi:10.1186/s13287-016-0319-y · Cited by 51
“However, it is still unclear which subsets of immune cells are involved in pulmonary fibrosis and how they affect the development of disease [10, 14], although it is conceivable that dysregulation of the immune system may be an important factor contributing to CTD-IP.”
BackgroundSchimmelpennink, M. C., Quanjel, M. J. R., Vorselaars, A. D. M., Wiertz, I. A., Veltkamp, M., van Moorsel, C. H. M., & Grutters, J. C. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1751614 · Cited by 51
“However, in sarcoidosis (as well as in cHP), fibrosis is a consequence of severe inflammation explaining lymphocytosis accompanied by excessive sIL-2R production [47].”
BackgroundVagotomy attenuates bleomycin-induced pulmonary fibrosis in mice
Song, N., Liu, J., Shaheen, S. P., Du, L., Proctor, M., Roman, J., & Yu, J. (2015) · Scientific Reports · doi:10.1038/srep13419 · Cited by 49
Neonatal hyperoxia increases airway reactivity and inflammation in adult mice
Kumar, V., Lakshminrusimha, S., Kishkurno, S., Paturi, B., Gugino, S. F., Nielsen, L. C., Wang, H., & Ryan, R. M. (2016) · Pediatric Pulmonology · doi:10.1002/ppul.23430 · Cited by 48
Mathematical modeling of liver fibrosis
Friedman, A., & Hao, W. (2016) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2017010 · Cited by 47
Regulatory T Cells in Respiratory Health and Diseases
Singh, R. V., Alape, D., de Lima, A., Ascanio, J., Majid, A., & Gangadharan, S. P. (2019) · Pulmonary Medicine · doi:10.1155/2019/1907807 · Cited by 47
Intravenous Immunoglobulin as Potential Adjunct Therapy for Interstitial Lung Disease
Hallowell, R. W., Amariei, D. E., & Danoff, S. K. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201603-179ps · Cited by 46
Modeling DNA damage-induced pneumopathy in mice: insight from danger signaling cascades
Wirsdörfer, F., & Jendrossek, V. (2017) · Radiation Oncology · doi:10.1186/s13014-017-0865-1 · Cited by 47
“The conflicting findings on the role of lymphocytes in BLM-induced pulmonary fibrosis have been summarized and discussed earlier elsewhere [224].”
InfluentialT‐Helper 2 Lymphocyte Immunophenotype Is Associated With Iatrogenic Laryngotracheal Stenosis
Hillel, A. T., Ding, D., Samad, I., Murphy, M. K., & Motz, K. (2018) · The Laryngoscope · doi:10.1002/lary.27321 · Cited by 46
“anisms of stimulation or attenuation with fibroblasts in the trachea, it is unlikely that universal T-lymphocyte depletion would be therapeutically beneficial in patients with iLTS, irrespective of systemic side effects.(38) A more”
BackgroundSpagnolo, P., Tonelli, R., Samarelli, A. V., Castelli, G., Cocconcelli, E., Petrarulo, S., Cerri, S., Bernardinello, N., Clini, E. M., Saetta, M. P., et al. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2114897 · Cited by 45
“In other words, Th1 cells are expected to be antifibrotic, whereas Th2 cells are likely to be profibrotic [94].”
BackgroundThe foreign body response: emerging cell types and considerations for targeted therapeutics
Yang, B., Rutkowski, N., & Elisseeff, J. H. (2023) · Biomaterials Science · doi:10.1039/d3bm00629h · Cited by 46
LncRNA GAS5 attenuates fibroblast activation through inhibiting Smad3 signaling
Tang, R., Wang, Y.-C., Mei, X., Shi, N., Sun, C., Ran, R., Zhang, G., Li, W., Staveley-O’Carroll, K. F., Li, G., et al. (2020) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00059.2020 · Cited by 45
Luzina, I. G., Lockatell, V., Hyun, S. W., Kopach, P., Kang, P. H., Noor, Z., Liu, A., Lillehoj, E. P., Lee, C., Miranda-Ribera, A., et al. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00346.2015 · Cited by 45
Self-citationThakur, C., Wolfarth, M. G., Sun, J., Zhang, Y., Lu, Y., Battelli, L. A., Porter, D. W., & Chen, F. (2015) · Oncotarget · doi:10.18632/oncotarget.2914 · Cited by 44
Latent infection by γherpesvirus stimulates profibrotic mediator release from multiple cell types
Stoolman, J. S., Vannella, K. M., Coomes, S. M., Wilke, C. A., Sisson, T. H., Toews, G. B., & Moore, B. B. (2010) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00028.2010 · Cited by 44
Association between lysyl oxidase and fibrotic focus in relation with inflammation in breast cancer
Jeong, Y. J., Park, S., Mun, S., Kwak, S. G., Lee, S., & Oh, H. K. (2017) · Oncology Letters · doi:10.3892/ol.2017.7617 · Cited by 42
“…--------- --------- --------- --------- --- --- --------- --------- --------- --------- --------- --------- --- - -------- --------- --------- ------- --------- --------- ------- --------- --------- --------- --------- --------- --------- ---- and T‑lymphocytes in fibrotic tissue (18,25,26).”
Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects
Overed-Sayer, C. L., Miranda, E., Dunmore, R., Marin, E. L., Beloki, L., Rassl, D. M., Parfrey, H., Carruthers, A. M., Chahboub, A., Koch, S., et al. (2020) · Thorax · doi:10.1136/thoraxjnl-2019-214000 · Cited by 40
Permanent alveolar collapse is the predominant mechanism in idiopathic pulmonary fibrosis
Todd, N. W., Atamas, S. P., Luzina, I. G., & Galvin, J. R. (2015) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2015.1067609 · Cited by 40
“example, pulmonary T lymphocytes may increase or decrease extracellular matrix (ECM) deposition depending on their phenotype and the overall milieu in the lung [35,36].”
BackgroundSelf-citationShimbori, C., Bellaye, P., Kolb, P., & Kolb, M. R. J. (2017) · Milestones in drug therapy · doi:10.1007/978-3-0348-0977-1_3 · Cited by 38
Impact of Treg on other T cell subsets in progression of fibrosis in experimental lung fibrosis
Chakraborty, K., Chatterjee, S., & Bhattacharyya, A. (2018) · Tissue and Cell · doi:10.1016/j.tice.2018.06.003 · Cited by 38
Biologic Treatments in Interstitial Lung Diseases
Karampitsakos, Τ., Vraka, A., Bouros, D. E., Liossis, S. C., & Τzouvelekis, Α. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00041 · Cited by 39
Mammalian Neuraminidases in Immune-Mediated Diseases: Mucins and Beyond
Lillehoj, E. P., Luzina, I. G., & Atamas, S. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.883079 · Cited by 37
Self-citationCutting edge: FasL+ immune cells promote resolution of fibrosis
Wallach‐Dayan, S. B., Elkayam, L., Golan‐Gerstl, R., Konikov-Rozenman, J., Zisman, P., Richter-Dayan, M., Arish, N., & Breuer, R. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.02.006 · Cited by 34
Aschner, Y., Khalifah, A. P., Briones, N. J., Yamashita, C. M., Dolgonos, L., Young, S. K., Campbell, M., Riches, D. W. H., Redente, E. F., Janssen, W. J., et al. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.01.016 · Cited by 34
Oligonucleotide-targeting periostin ameliorates pulmonary fibrosis
Tomaru, A., Kobayashi, T., Hinneh, J. A., Tonto, P. B., D’Alessandro‐Gabazza, C. N., Fujimoto, H., Fujiwara, K., Takahashi, Y., Ohnishi, M., Yasuma, T., et al. (2017) · Gene Therapy · doi:10.1038/gt.2017.80 · Cited by 34
Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis?
Clarke, D. L., Murray, L. A., Crestani, B., & Sleeman, M. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.010 · Cited by 33
Li, Y., Chen, S., Li, X., Wang, X., Li, H., Ning, S., & Chen, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.762594 · Cited by 32
“Th1 cells and their secretory products such as IL-12 (a potent inducer of IFN-g) are considered as being anti-fibrotic (44, 45).”
BackgroundThe Effect of Nintedanib on T-Cell Activation, Subsets and Functions
Ubieta, K., Thomas, M. J., & Wollin, L. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s288369 · Cited by 31
Wang, Q., Xie, Z., Wu, Q., Jin, Z., Yang, C., & Feng, J. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001288 · Cited by 30
“production of IFNg in a bleomycin-induced animal model of IPF.([116]) Inhibiting Th1 differentiation by targeting of the transcription factor T-bet increased bleomycin-induced lung injury.”
BackgroundCoagulation and Autoimmunity in Scleroderma Interstitial Lung Disease
Ludwicka, A., Silver, R. M., & Bogatkevich, G. S. (2010) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2010.10.002 · Cited by 29
“Various fibrotic diseases of lungs including SSc-ILD are frequently associated with excessive accumulation of T lymphocytes, which is 1 of the major inflammatory cell type (54,55).”
BackgroundInfluentialVaccinia vaccine–based immunotherapy arrests and reverses established pulmonary fibrosis
Collins, S. L., Chan‐Li, Y., Oh, M. H., Vigeland, C. L., Limjunyawong, N., Mitzner, W., Powell, J. D., & Horton, M. R. (2016) · JCI Insight · doi:10.1172/jci.insight.83116 · Cited by 28
Pulmonary Vaccination as a Novel Treatment for Lung Fibrosis
Collins, S. L., Chan‐Li, Y., Hallowell, R. W., Powell, J. D., & Horton, M. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031299 · Cited by 28
“space [8,9].”
Fan, G., Liu, J., Wu, Z. S., Li, C., & Zhang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1049361 · Cited by 27
“CD4 T cells may regulate pulmonary fibrosis in multiple ways (63, 72).”
BackgroundVerret, V., Wassef, M., Pelage, J., Ghegediban, S. H., Jouneau, L., Moine, L., Labarre, D., Golzarian, J., Schwartz-Cornil, I., & Laurent, A. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.09.001 · Cited by 24
“In addition, in other situations including pulmonary fibrosis, lymphocytes are suspected to regulate the accumulation of extracellular matrix, particularly collagen [84].”
BackgroundIL-32γ attenuates airway fibrosis by modulating the integrin-FAK signaling pathway in fibroblasts
Hong, G. H., Park, S., Kwon, H., Bang, B., Lee, J., Kim, S., Pack, C., Kim, S., Moon, K., Kim, T., et al. (2018) · Respiratory Research · doi:10.1186/s12931-018-0863-3 · Cited by 24
Lacy, S. H., Epa, A. P., Pollock, S. J., Woeller, C. F., Thatcher, T. H., Phipps, R. P., & Sime, P. J. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00565.2016 · Cited by 24
“Both CD4 and CD8 T cells have been found in the bronchoalveolar lavage fluid of IPF patients, and the ratio generally skews toward high CD8 T cell numbers (19, 34, 48).”
Yoshida, T., Ohnuma, A., Horiuchi, H., & Harada, T. (2011) · Journal of Toxicologic Pathology · doi:10.1293/tox.24.9 · Cited by 21
Lei, L., He, Z., Zhao, C., Sun, X., & Zhong, X. (2014) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12522 · Cited by 20
Xing, X.-Y., Qiang, W., Bao, J.-L., Yang, R., Hou, J. W., Tao, K., Meng, Z., Zhang, J., Zhang, A., & Sun, X. (2020) · Chinese Herbal Medicines · doi:10.1016/j.chmed.2020.05.002 · Cited by 19
Mutlu, S. M., Scalise, M. C., Philip, S., Gazdhar, A., & Fabian, B. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00945-7 · Cited by 19
“However, evidence from the animal model suggests that the whole T cell compartment plays an important role in the establishment of fibrosis after initial inflammatory processes induced by bleomycin injury [13].”
BackgroundDing, M., Pei, Y., Zhang, C., Qi, Y., Xia, J., Hao, C., & Yao, W. (2022) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2022.114401 · Cited by 18
Metadata
- Authors
- Luzina, I. G., Todd, N. W., Iacono, A. T., & Atamas, S. P.
- Affiliations
- Baltimore VA Medical Center (US)
- Corresponding author
- Atamas, Sergei P
- Venue
- Journal of Leukocyte Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-10-25
- Volume
- 83
- Issue
- 2
- Pages
- 237-244
- ISSN
- 0741-5400 (ISSN-L)
- 1938-3673
- OpenAlex
- W2164998164
- Cited by
- 163
- References
- 59
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 7 · 2023: 12 · 2022: 12 · 2021: 7 · 2020: 9 · 2019: 7 · 2018: 13 · 2017: 9 · 2016: 8 · 2015: 10 · 2014: 8 · 2013: 10 · 2012: 12
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Leukocyte Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1R01HL074067)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pulmonary fibrosis, T cells, T cell phenotype, extracellular matrix accumulation, collagen deposition, antifibrotic mechanism, lung inflammation
- MeSH terms
- Animals, Connective Tissue Diseases, Disease Models, Animal, Extracellular Matrix, Humans, Inflammation, Lymphocyte Depletion, Lymphokines, Mice, Nude, Pulmonary Fibrosis, T-Lymphocyte Subsets, Mice, SCID, Lung Diseases, Interstitial, CD28 Antigens, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.